Eli Lilly is one of the world's largest pharmaceutical companies, and today the dominant force in the incretin (GLP-1) revolution treating obesity and type-2 diabetes. Its core business is discovering, manufacturing and selling patent-protected medicines; the crown jewels are tirzepatide — sold as Mounjaro (diabetes) and Zepbound (obesity) — which together drive roughly two-thirds of revenue and are growing well over 50% a year. What sets Lilly apart is the combination of best-in-class clinical efficacy (its drugs out-perform rivals on weight loss), a multi-billion-dollar bet on incretin manufacturing capacity that few can match, and a deep late-stage pipeline beyond obesity — oncology (Verzenio, Jaypirca), Alzheimer's (Kisunla), immunology and now neuroscience. For a reader: think of it as the premium, capacity-advantaged leader of the fastest-growing drug market in a generation, priced accordingly.
Lifecycle & sector: Large-cap Health Care (Drug Manufacturers — General) in an accelerated-growth phase — a rare combination of >50% revenue growth and 45%+ operating margins, driven by the tirzepatide (Mounjaro/Zepbound) ramp. Scored on pharma metrics (R&D efficiency, patent-cliff exposure, pipeline depth, ROIC), not on a mature-pharma lens.
| Sub-signal | Value | Context | Score |
|---|---|---|---|
| Revenue trajectory | +55.5% YoY (Q1'26 $19.8B); TTM $72.2B | Pharma median low-single-digit — top-decile, still accelerating | 95 |
| Profitability vs peers | Op margin 45.9%, gross 83.5%, net 35.0% | Well above large-pharma medians; margins expanding on scale | 90 |
| Cash generation | FCF/share ~$15; OCF margin 28% | Real but capex-heavy (incretin capacity build) — FCF conversion depressed by design | 62 |
| Balance sheet | Interest coverage 37.5×; current ratio 1.50 | Investment-grade; ample headroom | 82 |
| ROE / ROIC | ROE ~81%; ROIC top-quartile (92nd pct) | Elite capital returns; FMP ROE/ROA sub-scores both 5/5 | 92 |
| Rival | Threat type | Share trajectory vs LLY | Moat-erosion vector |
|---|---|---|---|
| Novo Nordisk (NVO) | Direct GLP-1 rival | LLY gaining overall (~60% US weight-loss share; Zepbound out-sells Wegovy on efficacy) but losing the ORAL sub-segment near-term | Oral Wegovy launch captured ~89% of oral scripts; Lilly's oral orforglipron (marketed as Foundayo per recent coverage) had a slow start |
| Pfizer (PFE) | Emerging entrant | Behind, but funded (Metsera / MET-097i, monthly dosing) | Pipeline threat to future pricing/share, not current |
| Amgen (AMGN), Roche | Pipeline entrants | Phase-3 (MariTide) / mid-stage | Longer-dated class dilution |
The anchor (warranted-multiple): discount rate r = 4.5% (10-Y, per the 20 Jul macro report) + 4.5% ERP + 0 risk add-on (Quality ≥65) = 9.0%; disciplined growth g_near = 10% (Health-Care 'cyclical/normal' cap — consensus ~22% EPS CAGR haircut 25% to ~17%, then capped at the sector-achievable 10%), g_term = 3%. Two-stage → warranted ≈ 23×. The Health-Care guardrail floor is 22×.
| Multiple | LLY | Warranted / floor | Read |
|---|---|---|---|
| Clean forward P/E (FY26) | ~32.4× | 23× warranted · 22× floor | 1.39× warranted → Expensive |
| Forward P/E (FY27) | ~25.4× | — | Growth pulls it down but still > floor |
| TTM P/E | 40.7× | 22× floor | 1.77× warranted |
| FCF yield (universal anchor) | ~1.3% | >5% attractive | Very expensive on cash |
| EV/EBITDA · P/B · P/S | 33.4× · 32.9× · 14.9× | — | Rich on every lens |
Street cross-check (secondary to the anchor): consensus target $1,315.42 (median $1,300, high $1,500, low $1,135) → +14.7% upside; grades 33 Buy / 9 Hold / 3 Sell (~73% bullish); FMP rating B+ (overall 3/5) — its P/E (2/5) and P/B (1/5) sub-scores flag exactly this rich valuation, while ROE/ROA score 5/5. The Street is constructive, but analyst upside cannot lift an intrinsic-anchor Expensive read into Fair.
LLY's fortunes are dominated not by a commodity price but by the trajectory of GLP-1/incretin demand and Lilly's ability to out-innovate and out-manufacture Novo Nordisk. This is a demand/pipeline driver, so the commodity price-trend overlay (Step 2b) does not apply — there is no metal to roll over; the analogue risk is the competitive/oral-share dynamic, captured below and in §11.
| Horizon | Read | Evidence (dated) |
|---|---|---|
| Historical (12–24m) | Explosive | Obesity TAM inflected; Mounjaro/Zepbound ramp took Lilly to ~60% US weight-loss share |
| Current | Strong but contested | Goldman raised its 2030 obesity-drug forecast +15% (Jul'26); but Novo's oral Wegovy launch took ~89% of oral scripts, and Lilly's oral (Foundayo) started slowly |
| Forward (6–12m) | Tailwind | Retatrutide Phase-3 (bariatric-surgery-like efficacy); orforglipron oral label expansions; non-GLP-1 pipeline +160% |
The newest MacroDriver report (20 Jul, regime = Stagflation-lite / energy-supply-shock from the Iran–Hormuz escalation) rates Health Care (XLV) Outperform across all three horizons (O/O/O) — a defensive-rotation bid as the oil tax pressures cyclicals and long-duration growth. That is a Tailwind, improved from Neutral on the 6 Jul report (XLV was U/N/O in June). Source: sector-map (LLY is not an individual line in the macro watchlist). Crucially, pressure only amplifies a directional base signal: LLY's base is HOLD (Expensive), HOLD never amplifies, and the Expensive band would block STRONG BUY anyway — so the tailwind is supportive context, not a signal change.
Source: sector-map · Macro report 2026-07-20
Timing is a mixed picture that nets to a modest 56 — the multi-timeframe trend is bullish (monthly/weekly/daily all up, price above the 50- and 200-day averages) but near-term momentum is rolling over after the −2.7% drop from the $1,249 all-time high.
| Sub-signal | Read | Score |
|---|---|---|
| MTF confluence | Higher-TF up, intraday oversold — pullback in uptrend | 60 |
| Risk-reward (stop distance) | ~6% to the $1,079 stop; price mid-range after an 8% pullback off the high | 50 |
| Relative strength | Outperformed SPY & XLV over 3m (Health-Care leadership); cooling near-term | 72 |
| Macro overlay (weight 0.10, low-sensitivity) | Defensive-rotation tailwind (XLV O/O/O) | 68 |
| Sentiment (grades/news) | All 'maintain' — 33 Buy/9 Hold/3 Sell; news tone positive but split on oral share | 58 |
| Catalyst cluster | Q2 earnings ~Aug 6 the main event; calendar otherwise clear | 70 |
short_entry_confirmed = false. Moot here, since the Valuation-Ceiling gate already caps every horizon at HOLD.| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-07-29 | Fed Interest Rate Decision (hold 3.75% exp) | High | 3.75% | 3.75% | Low | Pharma is low macro-sensitivity; broad-market only |
| 2026-07-30 | Q2 GDP · Core PCE (Jun) | High | 1.1% · 0.3% | 2.1% · 0.3% | Low | Defensive sector — indirect at most |
| ~2026-08-06 | LLY Q2 2026 earnings (company event) | High | — | — | Yes | The binding catalyst — franchise revenue, oral-script trajectory, guidance |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-07-14 | CPI YoY (Jun) | 3.5% | 3.8% | −7.9% (soft) | Risk-on for duration; June's soft print (macro expects July to re-accelerate on gasoline) |
| 2026-07-17 | Michigan Consumer Sentiment (Jul) | 54.4 | 51.0 | +6.7% (beat) | Mildly risk-on; little direct read for pharma |
LLY is a low macro-sensitivity defensive name — the FOMC (Jul 29), Q2 GDP and Core PCE (Jul 30) matter to the tape but barely to Lilly's cash flows. The one binding event is the company's own Q2 2026 earnings (~Aug 6), where the oral-script trajectory and franchise guidance are the swing factors. This is why the next update reschedules to just after it.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend ↑ | Bullish | 64 | +, rising | S: 972 · R: 1134 | Resistance breakout | 0.45× |
| Weekly | Uptrend ↑ | Bullish | 60 | +, rising | S: 977 · R: 1249 | Resistance breakout | 0.18× |
| Daily | Strong up ↑ | Bullish (softening) | 55 | −, rolling over | S: 1079 · R: 1183/1249 | None | 0.88× |
| Hourly | Strong down ↓ | Bearish | 30 | − (oversold) | S: 1134 · R: 1189 | Breakdown | — |
| 15-min | Strong down ↓ | Bearish | 35 | −, turning up | S: 1142 · R: 1187 | Breakdown | — |
| Confluence: Bullish (higher-TF uptrend, near-term pullback) · MTF Score 60 | |||||||
The higher timeframes (monthly/weekly/daily) remain in clean uptrends, with price above both the 50-day ($1,109) and 200-day ($1,007) averages. The intraday charts are oversold (RSI 30/35) after today's −2.7% drop from the 6 Jul all-time high of $1,249 toward $1,147 — a textbook pullback-in-an-uptrend, not a trend break. The daily MACD histogram has just rolled negative, so near-term momentum is fading. Dip-buy zone to watch: $1,079–$1,109; a daily reclaim of ~$1,180 on volume would restore momentum.
LLY 6-month daily (19 Jan – 19 Jul 2026) with SMA50. The late-June breakout to $1,249, then the pullback toward $1,147 — still well above the rising 50- and 200-day averages.
Retatrutide launches strongly and orforglipron/Foundayo scales; Lilly defends overall weight-loss share; obesity-TAM upgrades (Goldman-style) continue and the premium multiple holds. ≈ +26% from $1,146.90. Trigger: strong Q2 franchise beat + upbeat oral trajectory.
The GLP-1 franchise compounds at ~15% EPS CAGR, the pipeline delivers, and the multiple normalises modestly toward the high-20s — tracking the consensus median (~$1,300). ≈ +12.5%. The probability-weighted centre of gravity.
Competitive trigger (elevated): Novo's oral Wegovy keeps taking the oral segment, Foundayo underperforms, US MFN/Medicare drug-pricing bites margins, and the ~32×/40× multiple compresses toward the ~23× warranted anchor. ≈ −20%. This is the live risk the elevated competitive threat feeds.
Forecast: Fundamental group — opens on a pullback into the $1,079–$1,100 zone; reachable given the intraday downtrend, ~1–2 weeks — Moderate. Technical group — opens on a daily reclaim of ~$1,180 on >1.5× volume OR a confirmed higher-low bounce off $1,079 — Moderate. Catalyst group — event-gated to Q2 earnings ~Aug 6 (a >+5% guided-up reaction) — Low / event-dependent. Net: no entry path is open today (conviction = Wait); the most reachable is the dip into $1,079–$1,100.
Forecast: Stop-Loss unlikely near-term — price is ~6% above $1,079. No thesis-invalidation condition is live. The monitored risk is the competitive/oral-share read, which resolves at Q2 earnings ~Aug 6.
What you're risking: you'd be buying above fair value (~$1,100), into a daily tape that has just rolled over, and ahead of Q2 earnings (~Aug 6). No entry rule is met (Wait, 0/3). FCF yield is only ~1.3%, so there's little income to collect while you wait. What you're gaining: immediate exposure to the base/bull upside and to the retatrutide/oral/pipeline optionality you'd own for free. Read: acting now overpays on the anchor — waiting for the $1,079–$1,100 dip zone or the post-earnings confirmation materially improves the deal.
What you're protecting: the −20% bear if the oral-share/drug-pricing risks bite. But no exit rule is triggered right now — the stop is clear, there's no thesis break, and you're not at the profit target. Read: this is a Hold / accumulate-on-weakness zone, not a mechanical sell; trim only into $1,290+ with RSI > 70.
Position sizing not computed — no allocation or portfolio role was specified. Context only: daily ATR ≈ $38 (~3.3% daily expected move); beta ≈ 0.52 (defensive, low-vol); price sits ~78% up its 52-week range ($624–$1,249). The §12 Conviction Ladder reads Wait (0/3 entry paths), so the framework's guidance is to wait for a path to open — a pullback into $1,079–$1,100 or a post-earnings confirmation — rather than initiate here. This is not advice.
{
"ticker": "LLY",
"date": "2026-07-20",
"version": "v6",
"company": "Eli Lilly and Company",
"currency": "USD",
"exchange": "NYSE",
"exchange_ticker": "NYSE:LLY",
"isin": "US5324571083",
"api_ticker": "LLY",
"analysis_status": "on-going",
"lifecycle_stage": "large_cap_pharma_accelerated_growth",
"sector": "Health Care",
"gics_sector": "Health Care",
"country": "United States",
"finder_ticker": "LLY",
"price_at_rating": 1146.9,
"signal_short": "HOLD",
"signal_medium": "HOLD",
"signal_long": "HOLD",
"primary_signal": "HOLD",
"quality_score": 84,
"valuation_score": 37,
"timing_score": 56,
"driver_score": 80,
"economic_alignment_stance": "Trend-Following",
"economic_alignment_conviction": 62,
"economic_alignment_pressure": "Tailwind",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-20",
"economic_alignment_sector": "Healthcare (XLV) s=O / m=O / l=O",
"overall_confidence": 58,
"val_band": "expensive",
"warranted_multiple": 23,
"actual_multiple": 32,
"warranted_ratio": 1.39,
"val_multiple_basis": "clean forward FY26 P/E (~32x); TTM 40.7x",
"discount_rate_r": 9.0,
"risk_free_10y": 4.5,
"g_near": 10,
"g_term": 3,
"clean_pe": 32.0,
"clean_peg": 1.5,
"nonop_pct_of_net_income": -8,
"fcf_yield_pct": 1.3,
"moat_score": 69,
"roic_percentile_vs_peers": 92,
"industry_benchmark_name": "R&D Efficiency + Patent-Cliff Exposure (pharma)",
"industry_benchmark_score": 88,
"competitive_share_trajectory": "gaining",
"competitive_threat_level": "elevated",
"fair_value_est": 1100,
"stop_loss": 1080,
"target_price": 1290,
"scenario_base_target": 1290,
"scenario_bull_target": 1450,
"scenario_bear_target": 920,
"entry_groups_met": 0,
"entry_conviction": "Wait",
"exit_groups_live": 0,
"exit_action": "Hold",
"short_entry_confirmed": false,
"hard_gate_state": "caution",
"gates_triggered": [
"Valuation Ceiling"
],
"gates_caution": [
"US drug-pricing (MFN/Medicare) overhang",
"Elevated GLP-1 competition (Novo oral Wegovy)"
],
"do_not_buy_triggers": [],
"analyst_consensus_target": 1315.42,
"analyst_target_high": 1500,
"analyst_target_low": 1135,
"analyst_target_median": 1300,
"analyst_target_upside_pct": 14.7,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 73.3,
"analyst_coverage_count": 45,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"fmp_rating": "B+",
"fmp_overall_score": 3,
"next_update_date": "2026-08-03",
"next_update_basis": "default +14d (Q2 2026 earnings ~Aug 6 just beyond window)",
"prior_report": "calibration-LLY-20260706-1740.json",
"prior_primary": "HOLD",
"changes_note": "HOLD/HOLD/HOLD held. Price -4.4% to $1,146.90 off the $1,249 ATH; forward P/E compressed ~34->32 as price fell but still Expensive vs ~23x warranted / 22x HC floor -> Valuation-Ceiling gate still binds. Economic Alignment upgraded Neutral->Trend-Following (pressure Neutral->Tailwind) as XLV moved to O/O/O. Driver 78->80. Timing 58->56 (daily MACD rolled over). orforglipron milestone: undated approval -> now launched (Foundayo, per coverage); Novo oral Wegovy strong keeps competitive threat elevated. Entry Wait."
}
HOLD held across all three horizons (Short/Medium/Long). Elite Quality (84) and a Strong-Tailwind driver (80) are overruled by an Expensive valuation (37) — the Valuation-Ceiling gate binds because the clean forward P/E (~32×) and TTM (40.7×) both exceed the 22× Health-Care guardrail floor and ~1.4×+ the ~23× warranted multiple. No Do-Not-Buy trigger fires (LLY is not an AI-cohort name; growth is exceptional). Entry conviction Wait (0/3).